A phase I/II dose escalation trial of the intra prostatic injection of CG7870, a prostate specific antigen-dependent oncolytic adenovirus in patients with locally recurrent prostate cancer following definitive radiotherapy

被引：0
|
作者：
DeWeese, T
Arterbery, E
Michalski, J
Sylvester, JE
Terris, MK
Wilding, G
Yu, DC
Moore, L
Kimball, L
Ando, D
Kim, D
机构：
[1] Johns Hopkins Oncol Ctr, Baltimore, MD USA
[2] Wayne State Univ, Rochester, MI USA
[3] Washington Univ, Med Ctr, St Louis, MO USA
[4] Seattle Prostate Inst, Seattle, WA USA
[5] Stanford Univ, Med Ctr, Palo Alto, CA 94304 USA
[6] VA Palo Alto Hlth Care Syst, Palo Alto, CA USA
[7] Univ Wisconsin, Ctr Comprehens Canc, Madison, WI USA
[8] Cell Genesys Inc, Foster City, CA USA
来源：
MOLECULAR THERAPY | 2003年 / 7卷 / 05期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
1158
引用
收藏
页码：S446 / S446
页数：1
相关论文
共 35 条
  • [1] A phase I/II dose escalation trial of the intra prostatic injection of CG7870, a prostate specific antigen-dependent oncolytic adenovirus in patients with locally recurrent prostate cancer following definitive radiotherapy
    DeWeese, T
    Arterbery, E
    Michalski, J
    Sylvester, J
    Terris, MK
    Wilding, G
    CANCER GENE THERAPY, 2003, 10 : S13 - S14
  • [2] A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer
    Small, Eric J.
    Carducci, Michael A.
    Burke, James M.
    Rodriguez, Ron
    Fong, Lawrence
    van Ummersen, Lynn
    Yu, D. C.
    Aimi, Junko
    Ando, Dale
    Working, Peter
    Kirn, David
    Wilding, George
    MOLECULAR THERAPY, 2006, 14 (01) : 107 - 117
  • [3] A phase I/II dose finding trial of the intravenous injection of Cv787, a prostate specific antigen-dependent cytolytic adenovirus in patients with advanced hormone refractory prostate cancer (Hrpc)
    Small, EJ
    Carducci, M
    Wilding, G
    CANCER GENE THERAPY, 2001, 8 : S10 - S10
  • [4] A phase I trial of intraprostatic injection of CG7870 and 3d-conformal radiation therapy (3D-CRT) in patients with localized intermediate risk prostate cancer: Integrated oncolytic adenovirus and radiationmechanisms of interaction
    Senzer, N
    Corman, J
    Nemunaitis, J
    Ando, D
    Kirn, D
    Yu, DC
    Burke, J
    RADIOTHERAPY AND ONCOLOGY, 2006, 78 : S54 - S55
  • [5] Phase I dose-escalation trial of tremelimumab in combination with bicalutamide in patients with recurrent prostate cancer
    Lang, J. M.
    Staab, M. J.
    Liu, G.
    Wilding, G.
    McNeel, D. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [6] Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy
    Pruthi, RS
    Derksen, JE
    Moore, D
    Carson, CC
    Grigson, G
    Watkins, C
    Wallen, E
    CLINICAL CANCER RESEARCH, 2006, 12 (07) : 2172 - 2177
  • [7] A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy
    DeWeese, TL
    van der Poel, H
    Li, SD
    Mikhak, B
    Drew, R
    Goemann, M
    Hamper, U
    DeJong, R
    Detorie, N
    Rodriguez, R
    Haulk, T
    DeMarzo, AM
    Piantadosi, S
    Yu, DC
    Chen, Y
    Henderson, DR
    Carducci, MA
    Nelson, WG
    Simons, JW
    CANCER RESEARCH, 2001, 61 (20) : 7464 - 7472
  • [8] A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in subjects with prostate cancer
    Slovin, Susan F.
    Kehoe, Marissa
    Durso, Robert
    Fernandez, Celina
    Olson, William
    Gao, Jian P.
    Israel, Robert
    Scher, Howard I.
    Morris, Stephen
    VACCINE, 2013, 31 (06) : 943 - 949
  • [9] A phase I clinical trial of oncolytic adenovirus mediated suicide and interleukin-12 gene therapy in patients with recurrent prostate cancer
    Nyati, Shyam
    Stricker, Hans
    Barton, Kenneth L.
    Li, Piln
    Elshaikh, Mohamed
    Ali, Haythem
    Brown, Stephen L.
    Hwang, Clara
    Peabody, James
    Freytag, Svend O.
    Movsas, Benjamin
    Siddiqui, Farzan
    CANCER RESEARCH, 2023, 83 (08)
  • [10] A phase I dose-escalation trial of stereotactic body radiotherapy using 4 fractions for patients with localized prostate cancer
    Kainuma, Takuro
    Kawakami, Shogo
    Tsumura, Hideyasu
    Satoh, Takefumi
    Tabata, Ken-ichi
    Iwamura, Masatsugu
    Hayakawa, Kazushige
    Ishiyama, Hiromichi
    RADIATION ONCOLOGY, 2019, 14 (01)
1234